GlassScriptPhysician profile
Martin M Newcomb
NPI 1104821123
$1,360.86
in general payments reported to CMS, 2019-2025
39 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $86.46 · 2020: $399 · 2021: $842 · 2024: $33.97.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $33.97.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $33.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $165.50 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $135.63 | 2020-2021 | |
| Janssen Biotech, INC. | $70.10 | 2019-2021 | |
| Lilly USA, LLC | $68.92 | 2021 | |
| Genzyme Corporation | $57.43 | 2020-2021 | |
| Glaxosmithkline, LLC. | $46.24 | 2020-2021 | |
| Astrazeneca Pharmaceuticals LP | $44.07 | 2020-2021 | |
| Coherus Oncology, INC. | $43.91 | 2020-2021 | |
| Acceleron Pharma, INC. | $43.10 | 2020-2021 | |
| Morphosys, US INC. | $42.00 | 2021 | |
| Astellas Pharma US INC | $40.63 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $38.10 | 2020-2021 | |
| Incyte Corporation | $37.37 | 2021 | |
| Dova Pharmaceuticals | $36.51 | 2021 | |
| Abbvie INC. | $33.97 | 2024 |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmacosmos Therapeutics INC. | $33.02 | 2020-2021 | |
| Exelixis INC. | $31.02 | 2020-2021 | |
| Regeneron Healthcare Solutions, INC. | $29.78 | 2021 | |
| Global Blood Therapeutics, INC. | $28.31 | 2021 | |
| Rigel Pharmaceuticals, INC. | $26.63 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $26.53 | 2021 | |
| Novartis Pharmaceuticals Corporation | $25.78 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $25.27 | 2021 | |
| Tersera Therapeutics LLC | $24.50 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $18.19 | 2021 | |
| Daiichi Sankyo INC. | $17.16 | 2020 | |
| Innate Pharma, INC | $16.24 | 2020 | |
| Genentech USA, INC. | $16.17 | 2021 | |
| Janssen Pharmaceuticals, INC | $14.69 | 2021 | |
| Emd Serono, INC. | $13.32 | 2021 | |
| Beigene USA, INC. | $13.16 | 2021 | |
| Puma Biotechnology, INC. | $12.99 | 2020 | |
| Blueprint Medicines Corporation | $12.61 | 2020 | |
| Seagen INC. | $12.26 | 2021 | |
| Celgene Corporation | $12.17 | 2021 | |
| Deciphera Pharmaceuticals INC. | $12.14 | 2021 | |
| Gilead Sciences, INC. | $11.92 | 2021 | |
| Eisai INC. | $11.85 | 2021 | |
| Pfizer INC. | $11.67 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Martin Newcomb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.